When was Avenzo Therapeutics founded?

Avenzo Therapeutics was founded in 2022 and raised its 1st funding round within a year of its incorporation.

Where is Avenzo Therapeutics located?

Avenzo Therapeutics is headquartered in San Diego, United States.

Who is the current CEO of Avenzo Therapeutics?

Athena Countouriotis of Avenzo Therapeutics. They have also founded 1 company.

How many employees does Avenzo Therapeutics have?

As of Sep 30, 2026, the latest employee count at Avenzo Therapeutics is 72.

Is Avenzo Therapeutics a funded company?

Avenzo Therapeutics is a funded company, having raised a total of $446M across 3 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Sep 14, 2022.

How much is Avenzo Therapeutics worth?

The latest valuation of Avenzo Therapeutics is $***** as of Jan 01, 2026.

When was the latest funding round of Avenzo Therapeutics?

Avenzo Therapeutics' latest funding was a $***** Series B round on Aug 22, 2025, with participation from 14 investors. Its primary sector is Oncology. In United States, the Oncology sector has seen $6.54B in funding in 2026 to date.

Where does Avenzo Therapeutics rank among its competitors?

Avenzo Therapeutics ranks 153rd amongst 3422 active competitors, of which 1129 are funded. It stands 2nd in terms of total funding among its competitors. The most recent competitor to raise funding was Immuneel, which secured $10.5M in Jun, 2026.

Who are the top competitors of Avenzo Therapeutics?

Avenzo Therapeutics' top competitors include Jazz Pharmaceuticals, BeiGene and Kite Pharma. Among them, Immuneel secured the most recent funding round in June, 2026.

Avenzo Therapeutics - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of therapeutics for cancer treatment. It offers a pipeline of oncology therapies which include AVZO-021 is a selective inhibitor of CDK2 for advanced solid tumors and HR+/HER2-negative metastatic breast cancer, ARTS-023 is a selective CDK4 inhibitor for HR+ breast cancer, AVZO-1418 is a BsADC targeting EGFR and HER3 for non-small cell lung cancer, and VAC-103 BsADC targeting Nectin4 and TROP2 for urothelial and breast cancers.

Key Metrics

Founded Year

2022

Location

San Diego, United States

Stage

Series B

Total Funding

$446M in 3 rounds

Latest Funding Round

Series B, Aug 22, 2025, $*****

Post Money Valuation

$***** as on Jan 01, 2026

Investors

New Enterprise Associates & 16 more

Ranked

153^rd among 3422 active competitors

Employee Count

72 as on Sep 30, 2026

Similar Companies

Jazz Pharmaceuticals & 3029 more

View Avenzo Therapeutics' full profile

Avenzo Therapeutics is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
AVENZO THERAPEUTICS INC CIN: 883737798 , United States, Active	Apr 19, 2023	-	34 (As on Dec 31, 2024)	-

Avenzo Therapeutics has raised a total funding of $446M over 3 rounds. Its first funding round was on Sep 14, 2022. Its latest funding round was a Series B round on Aug 22, 2025 for $*****. 14 investors participated in its latest round. Avenzo Therapeutics has 17 institutional investors.

Here is the list of recent funding rounds of Avenzo Therapeutics:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Aug 22, 2025	1601624	Series B	1931899	2697177	1099858	3606013
Nov 18, 2024	2072962	Series A	6306073	7131128	2779872	Orbimed & 12 more
Sep 14, 2022	4913274	Series A	6582399	1596779	New Enterprise Associates & 3 more	INCE Capital & 3 more

Access funding benchmarks and valuations. Sign up today!

View details of Avenzo Therapeutics's funding rounds and investors

The founders of Avenzo Therapeutics are Athena Countouriotis and Mohammad Hirmand. Athena Countouriotis is the CEO of Avenzo Therapeutics.

Here are the details of Avenzo Therapeutics' key team members:

Athena Countouriotis: Co-Founder & CEO of Avenzo Therapeutics.
Mohammad Hirmand: Co-Founder & Chief Medical Officer of Avenzo Therapeutics.
Contact Info: 1 email address

View details of Avenzo Therapeutics's Founder profiles and Board Members

Avenzo Therapeutics' employee count trend

Avenzo Therapeutics has 72 employees as of Sep 26. Here is Avenzo Therapeutics's employee count trend over the years:

Employee count trend for Avenzo Therapeutics

Uncover Avenzo Therapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Avenzo Therapeutics include Jazz Pharmaceuticals, BeiGene and Kite Pharma. Here is the list of Top 10 competitors of Avenzo Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	77/100
3rd	Kite Pharma 2009, Los Angeles (United States), Acquired	Developer of cancer immunotherapy products using genetic engineering	$97.7M	Alta Partners, Amgen Business Development ... & 10 others	76/100
4th	Attovia 2023, Fremont (United States), Public	Developer of antibody-based therapeutics for immune-mediated diseases and oncology	$255M	Deep Track Capital, Goldman Sachs Asset Management ... & 13 others	72/100
5th	Tango Therapeutics 2017, Cambridge (United States), Public	Developer of drugs for the treatment of cancer	$165M	Boxer Capital, Casdin Capital & 8 others	72/100
6th	Elicio 2012, Cambridge (United States), Public	Developer of vaccines for treating cancer	$47.4M	Dreavent, Efung Capital & 5 others	72/100
7th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	71/100
8th	BioNTech 2008, Mainz (Germany), Public	Developer of immunotherapeutics for the treatment of cancer and other diseases	$861M	Fidelity Investments, Redmile Group & 28 others	71/100
9th	Erasca 2018, San Diego (United States), Public	Developer of small molecule based therapeutics for cancer	$300M	Cormorant Asset Management, Arch Venture Partners ... & 13 others	71/100
10th	Strand Therapeutics 2017, Cambridge (United States), Series B	Provider of platform to deliver mRNA therapeutics for multi functional treatments	$256M	Kinnevik, Playground Global & 19 others	71/100
153rd	Avenzo Therapeutics 2022, San Diego (United States), Series B	Developer of therapeutics for cancer treatment	$446M	Foresite Capital, Deep Track Capital & 15 others	60/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Avenzo Therapeutics's competitors? Click here to see the top ones

Avenzo Therapeutics has made no investments or acquisitions yet.

Here is the latest report on Avenzo Therapeutics's sector:

Free

Oncology - Sector Report

Edition: September, 2026 (75 Pages)

View all reports related to Avenzo Therapeutics

Media has covered Avenzo Therapeutics for a total of 11 events in the last 1 year, 6 of them have been about company updates and 3 about people movement.